Your GLP-1 Is Doing More to Your Brain Than You Think

Your brain runs on a currency called dopamine, and almost every drive you have, the hunger, the ambition, the sexual desire, the motivation to get off the couch, traces back to how freely that currency flows through a circuit that starts in an area called the ventral tegmental area, which most people call the VTA, and which functions as the brain's central reward-dispatch center.

That circuit works like this. Neurons in the VTA fire and release dopamine into a region called the nucleus accumbens, and that dopamine signal is what your brain uses to make you want things, pursue things, initiate things. The wanting comes first. The doing follows from the wanting. And the wanting, it turns out, can be dialed down by something most people using GLP-1 drugs have no idea is happening.

GLP-1 receptors sit inside the VTA, not just in the gut and the pancreas where most explanations stop, and when a GLP-1 drug like semaglutide or retatrutide activates those receptors, something specific happens to the wiring. The drug increases the firing of a class of neurons called GABA neurons, and GABA neurons function as the brake system of the brain, suppressing the activity of whatever they connect to. In this case, they connect to and suppress the dopamine-releasing neurons. So GLP-1 activation hits the brake on your reward-dispatch center, and the dopamine signal that normally makes you pursue things gets turned down.

That mechanism is not theoretical. A 2025 study in Science Advances demonstrated it directly in animal models, showing that GLP-1 receptor activation in the VTA increases GABA neuron firing and measurably suppresses dopamine neuron activity, reducing reward-seeking behavior. The pathway is real and it is operating in people using these drugs right now.

Here is the part that makes this clinically different from other causes of low drive. Researchers draw a distinction between two components of desire, something called "wanting," which is the anticipatory drive to seek a reward, and something called "liking," which is the hedonic pleasure you actually experience when the reward arrives. These are separate systems. They can be affected independently.

GLP-1 drugs appear to reduce wanting without reducing liking. A 2025 study on semaglutide found that the drug reduced reward-seeking behavior but did not diminish the hedonic response when a reward was received, and notably, the researchers actually observed enhanced VTA dopamine activity during the consummatory phase, meaning the pleasure of the moment was preserved or even slightly elevated, while the motivation to pursue that moment in the first place was suppressed.

That distinction explains something that confuses almost everyone this happens to. If you are on one of these drugs and sex happens, it feels fine. Nothing feels broken in the moment. The problem is you stopped initiating, stopped thinking about it, stopped feeling the pull toward it. And because nothing feels wrong when it happens, your brain never generates the signal that tells you something changed. You do not notice the absence of wanting because wanting is what would make you go looking for it.

This is also why it shows up differently than low testosterone or clinical depression. Both of those tend to reduce liking as well, so people notice something is wrong with how things feel. The GLP-1 suppression is quieter. It just removes the forward motion.

The dopamine pathway is one mechanism. There may be a second one running at the same time.

A 2026 clinical review published in Obesity Pillars proposed that GLP-1 agonists upregulate activity at a serotonin receptor called 5-HT2C, which is the same receptor implicated in the sexual side effects of SSRIs. That receptor, when activated, is well-documented to suppress sexual desire and delay arousal. It is the primary reason SSRI users report reduced libido even when their depression is improving. If GLP-1 drugs engage the same receptor, that is a second independent pathway reducing desire, and the two mechanisms would be additive.

The review also raised something worth understanding about why this gets missed clinically. Weight loss carries its own effects on mood, confidence, and libido, and those effects tend to run in the opposite direction, improving desire and self-reported sexual function. So in someone losing significant weight on a GLP-1, the brain suppression and the psychological benefit are pulling against each other, and the net result can look like nothing changed, even when both effects are substantial and operating simultaneously.

That camouflage is part of why the clinical picture has been hard to study cleanly. A 2024 randomized controlled trial using dulaglutide in healthy men over four weeks found no significant change in sexual function scores, which sounds reassuring, but dulaglutide has weaker central nervous system penetration than semaglutide, the four-week window may not be long enough to see the full effect, and running the trial in healthy men rather than people on weight-loss doses means the conditions were systematically different from the people most likely to be affected.

The confirmation that these drugs modulate the reward pathway in ways that extend beyond appetite is no longer in question. A 2025 randomized clinical trial in JAMA Psychiatry tested once-weekly semaglutide in 48 adults with alcohol use disorder and found meaningful reductions in alcohol consumption, craving scores, and heavy drinking days. The mechanism for that effect runs through the same VTA dopamine pathway. The drug does not selectively suppress appetite and leave everything else alone. It turns down the signal that makes you want things, and what you stop wanting depends on what your drive was pointed at to begin with.

The reversibility piece is straightforward. Semaglutide has a half-life of approximately one week, and retatrutide is similar. Once you stop, the drug clears, the GABA brake lifts off the dopamine neurons, and reward signaling returns to baseline within roughly four to five weeks. The person who comes back is the same person who left. The shift was pharmacological, not identity-level.

The deeper thing to understand here is what this reveals about how desire actually works. Most people experience wanting as something that just happens to them, as something that comes from within, and for most of their lives that is close enough to true. But wanting is a signal generated by a specific circuit, and that circuit has receptors on it, and those receptors respond to drugs, and when the drugs are doing their job so quietly that you cannot feel the side effect, the absence of wanting just feels like you.

That is the part most people are not being told.

---

References

1. Merkel R, Thapa N, Engel L, et al. 2025. An endogenous GLP-1 circuit engages VTA GABA neurons to regulate mesolimbic dopamine neurons and attenuate cocaine seeking. Science Advances, 119, eadr5051. Finding: GLP-1 receptor activation in the VTA increases GABA neuron firing, which suppresses dopamine neuron activity and reduces reward-seeking behavior. Source
2. Hurst K, et al. 2025. GLP-1 receptor agonist semaglutide reduces appetite while increasing dopamine reward signaling. Neurobiology of Disease and Treatment. Finding: Semaglutide reduced reward collection but did not diminish hedonic "liking" response, and actually enhanced VTA dopamine activity during consummatory phase. Source
3. Gelfand SG, Tveit RL, Simon JA. 2026. Clinical review of how glucagon-like peptide-1 agonist obesity medications decrease sexual desire, and a biopsychosocial model for why we don't 'see' it. Obesity Pillars, 17, 100233. Finding: GLP-1 agonists likely decrease sexual desire via 5-HT2C serotonergic upregulation same mechanism as SSRIs, but this is camouflaged by competing positive effects of weight loss. Source
4. Hendershot CS, et al. 2025. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry, 824, 395-405. Finding: Semaglutide reduced alcohol consumption, craving, and heavy drinking days in a Phase 2 RCT n=48, confirming reward pathway modulation extends beyond appetite. Source
5. Jalleh RJ, et al. 2024. Effects of the glucagon-like peptide-1 receptor agonist dulaglutide on sexuality in healthy men: a randomised, double-blind, placebo-controlled crossover study. eBioMedicine, 107. Finding: 4-week dulaglutide in healthy eugonadal men showed no change in sexual function scores null result, but short duration and weaker CNS penetration than semaglutide. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness